Elevation of IL-1β levels leads to chronic low-grade inflammation, cytokine profile changes and activation of innate immunity, and the increased expression of IL-1β in plasma/serum can alter lipid metabolism, causing hyperlipidemia (Sonnenschein and Meyle, 2000; Iacopino, 2001). This evidence concerns the gene IL1B and hyperlipidemia.